This is a double-blind, randomized, placebo-controlled, phase 3, multinational, multicenter study of AMG0001 (HGF plasmid) in subjects with Critical Limb Ischemia (CLI).
Study to Evaluate the Efficacy and Safety of AMG0001 in Subjects with Critical Limb Ischemia.